Introduction
Dopamine (DA) depletion using the competitive and reversible tyrosine hydroxylase inhibitor ␣-methylpara-tyrosine (AMPT) has been reported to result in an increase in human neostriatal DA D 2 receptor binding potential (D 2 RBP) in vivo. [1] [2] [3] However, to our knowledge the effects of DA depletion on DA D 1 receptors (D 1 R) in humans have not been studied. D 1 R positron emission tomography (PET) imaging studies have been performed, sometimes with contradictory results, in various neuropsychiatric disorders such as schizophrenia, 4 ,5 bipolar disorder, 6 idiopathic Parkinson's disease, [7] [8] [9] striatonigral degeneration, 7 Huntington's disease, [10] [11] [12] [13] [14] and narcolepsy. 15 Obtaining more information about the impact of the interaction between DA and D 1 R on radiotracer binding in vivo can help with the interpretation of those D 1 R PET studies. Animal studies using the radiotracer [ 3 H]SCH23390 show a 30-40% decrease in D 1 RBP, proportional to the extent of acute DA depletion. [16] [17] [18] This could be due to decreased D 1 R internalization 19 with a relative D 1 R increase at the cell membrane vs in the cytosol, resulting in decreased affinity for [ 3 H]SCH23390 due to changes in the ionic microenvironment. 20, 21 Therefore, in this study we assessed the effects of AMPT-induced DA depletion on neostriatal DA D 1 receptor binding potential (D 1 RBP) as well as on D 2 RBP using PET with [ 11 C]SCH23390 and with [ 11 C]raclopride, respectively, in six healthy subjects.
Results and conclusions

AMPT treatment resulted in catecholamine depletion
Treatment with AMPT resulted in significant decreases in plasma levels of the DA metabolite homovanillic acid (HVA) and of the norepinephrine metabolite 3-methoxy-4-hydroxyphenethyleneglycol (MHPG), and in significant increases in AMPT and prolactin levels ( Table 1) . The AMPT levels in our study were higher than the steady-state levels of 21 ± 7 g ml −1 (all values in this article are expressed as average ± standard deviation) obtained by Laruelle et al 1 and 21.4 ± 8.0 g ml −1 obtained by Fujita et al, 22 but within the same order of magnitude. Increasing oral AMPT administration from 4500 mg over 25 h to 5250 mg over 29 h resulted in a trend for further decrease in MHPG but not in HVA levels (two-tailed paired Student's t-test: df = 5, P = 0.064 and P = 0.897, respectively), AMPT levels (two-tailed paired Student's t-test: df = 5, P = 0.203), or prolactin levels (Wilcoxon's signed ranks test: df = 5, P = 0.343). These results suggest that the extent of DA depletion after oral ingestion of 4500 mg AMPT (during the D 1 R PET) and 5250 mg AMPT (during the D 2 R PET), respectively, was similar. 2). This is consistent with the D 2 RBP increase observed previously by our group using the same methodology in a different cohort of six healthy subjects. 3 However, the change observed in D 1 RBP, 4.3 ± 10.6%, was not significant (Figure 2 and Table 3 ). constant for [ 11 C]raclopride transfer from plasma to region of interest (ie, neostriatum), and KЈ 1 = rate constant for [ 11 C]raclopride transfer from plasma to reference region (ie, cerebellum). No direct measurements of regional cerebral blood flow or K 1 were performed in this study. With AMPT-induced DA depletion, a significant increase of 10.7 ± 5.0% was observed in R 1 (Table 2) . However, no significant correlations were observed between D 2 RBP and R 1 pre AMPT (r = 0.421, P = 0.406) or post AMPT (r = −0.339, P = 0.511), or between the percentage increase with AMPT in these parameters (r = −0.234, P = 0.655). Therefore, any possible AMPT-induced R 1 increase does not seem to be a significant contributing factor to the observed D 2 RBP increase.
AMPT treatment resulted in neostriatal D
The sample size in this study may have been insufficient to detect any subtle AMPT-induced D 1 RBP changes. 23 Assuming no AMPT-induced D 1 RBP changes occurred, the coefficient of variation of D 1 RBP measures with [ 11 C]SCH23390 PET in our study was 9.2 ± 5.9%, which is higher than the previously reported range of 2.3-3.6% using tissue-input Logan D 1 RBP values. 24 Since the [ 11 C]SCH23390 PET was done before the [ 11 C]raclopride PET after a lower total dose and duration of AMPT treatment, DA depletion could have been more pronounced during the D 2 R rather than the D 1 R measures. However, as mentioned above, no significant changes were observed in HVA, MHPG, AMPT and prolactin levels post 4500 mg vs 5250 mg AMPT. These data are compatible with: (1) a study that reported that administration of AMPT orally 1 g thrice daily for 24 h resulted in minimum HVA levels; 25 and (2) a recent [
11 C]raclopride PET study using a bolusplus-constant-infusion paradigm in which no significant differences in D 2 RBP increase were observed, neither in the whole neostriatum nor in any neostriatal subregion, at 24 h vs 48 h of oral administration of AMPT at 56.6 ± 3.8 mg kg −1 per 24 h. 26 
Implications of these findings
The lack of any substantial D 1 RBP change with AMPTinduced DA depletion is compatible with the lack of any significant D 1 RBP change observed in vivo with amphetamine-induced DA release 20, 21, 27, 28 or with gammabutyrolactone-induced acute DA depletion. 27 The D 1 RBP measures with increased or decreased DA release do not seem to be compatible with either an occupancy model (in which dopamine competes directly with 19 Therefore, based on the D 1 RBP decrease with DA depletion observed in the rodent literature, [16] [17] [18] we initially assumed that an internalization-externalization model might apply in which the affinity of SCH23390 would be higher for D 1 R in the cytosol than on the cell membrane. However, the latter has to our knowledge neither been experimentally validated nor refuted. Therefore, it could be that for SCH23390 and other radiotracers used thus far, 15, 20, 21, 28 there is actually no substantial difference in affinity for membranous vs intracellular D 1 R. In that case, an internalization-externalization model might still be adequate, but this model would not be useful unless D 1 R radiotracers would be developed that show these affinity differences. Alternatively, more complex models may be necessary.
The AMPT-induced D 2 RBP increase observed in this study and in our previous study 3 could not only be compatible with an occupancy model but also with an internalization-externalization model. 20, 21 Similar to D 1 R, it is generally believed that DA or D 2 R agonists induce D 2 R internalization. 29, 30 This may, probably due to changes in the ionic D 2 R microenvironment, 20, 21 result in a decreased affinity in vivo for some benzamides such as [ 11 31 Therefore, with DA depletion a reversal of D 2 R distribution from the cytosol to the cell membrane compartment could result in an increased affinity for some benzamides and thus in an increased binding potential of these radioligands.
20,21
Conclusions
We conclude that AMPT-induced DA depletion did not result in any substantial D 1 RBP change, although it resulted in a significant D 2 RBP increase. Probably more complex models are necessary to describe the interaction between DA and D 1 R radiotracers in vivo.
Methods
Human subjects
The study was approved by the Human Subjects Review Committee of the University of Toronto and has been carried out in accordance with the Helsinki Declaration of 1975. Five women and one man, age 27 ± 8 years and all right-handed, entered the study. Exclusion criteria were: (1) psychiatric diagnosis on Axis I as assessed by the Structured Clinical Interview for DSM-IV, nonpatient version; (2) serious medical or neurological illness or significant head injury by history or on physical examination or based on laboratory studies (complete blood count, fasting blood glucose, basic urea nitrogen, creatinine, electrolytes, thyroid function tests, liver function tests, urinalysis, EKG); (3) lifetime history of alcohol or substance dependence; (4) history of alcohol or substance abuse during the 6 months preceding the study; (5) recent substance use on urine toxicology screen; (6) treatment with any psychotropic medications by history or on urine toxicology screen; (7) pregnancy by history or on urine ␤HCG test.
Depletion regimen and clinical monitoring
Each subject was scanned four times, twice in the baseline state (D 1 RPET1 and D 2 RPET1, day 1) and twice after DA depletion (D 1 RPET2 at 1-2 pm and D 2 RPET2 at 5-6 pm, day 3). DA depletion was induced by oral administration of in total 5250 mg AMPT over 29 h. AMPT was administered orally in doses of 750 mg each Molecular Psychiatry at the following times: at 10 am, 1.30 pm, 6 pm, and 10 pm on day 2, and at 7 am, 11 am and 3 pm on day 3. During AMPT administration, subjects remained under direct observation at the PET Centre during the day and on a psychiatric inpatient unit during the night. To prevent the formation of AMPT crystals in the urine, subjects were instructed to drink at least 4 litres of fluids per day, starting on day 2. 32 In addition, in order to alkalinize the urine which increased AMPT solubility, sodium bicarbonate 1.2 g orally was given at 10 pm on day 1 and at 7 am on day 2. Urine samples were collected at 3 pm on day 2 and at 7 am on day 3 to examine for the presence of AMPT crystals.
Catecholamine metabolites plasma analysis
Plasma HVA and MHPG samples were collected at 10 am (day 1), at 10 am (day 2 pre AMPT), at 3 pm (day 2 post 1500 mg AMPT), at 1 pm (day 3 post 4500 mg AMPT), and at 5 pm (day 3 post 5250 mg AMPT). Plasma HVA levels were measured as the methylated then acetylated derivative using Gas ChromatographyMass spectrometry (GCMS) with selected ion monitoring. 33 Plasma MHPG levels were measured as the 4-acetyl-di-trifluoro-acetyl derivative using GCMS with selected ion monitoring. 34 AMPT plasma analysis Plasma AMPT samples were collected at 3 pm (day 2 post 1500 mg AMPT), at 1 pm (day 3 post 4500 mg AMPT), and at 5 pm (day 3 post 5250 mg AMPT). Plasma AMPT concentrations were measured as the pentafluorobenzoyl derivative using GCMS with selected ion monitoring. 35 Prolactin plasma analysis Plasma prolactin samples were collected at 10 am (day 1), at 10 am (day 2 pre AMPT), at 3 pm (day 2 post 1500 mg AMPT), at 1 pm (day 3 post 4500 mg AMPT), and at 5 pm (day 3 post 5250 mg AMPT). Plasma prolactin levels were measured using microparticle enzyme immunoassay technology.
36
D 1 R and D 2 R PET data acquisition D 1 R PET images were obtained with a GEMS PC2048-15B camera (General Electric Medical Systems, Milwaukee, WI, USA) in fifteen 1-min frames followed by nine 5-min frames after [
11 C]SCH23390 bolus injection (pre AMPT: 370 ± 24 MBq, specific activity 31.6 ± 11.7 GBq mol −1 ; post AMPT: 351 ± 19 MBq, specific activity 34.6 ± 5.5 GBq mol −1 ). D 2 R PET images were obtained in five 1-min frames followed by twenty 2-min frames and three 5-min frames after [ ). There was no significant difference in the pre-and post-AMPT injected radioactivity and specific activity of [ 11 C]SCH23390 (two-tailed paired Student's t-test: df = 5, P = 0.171 and P = 0.584, respectively) or [
11 C]raclopride (two-tailed paired Student's t-test: df = 5, P = 0.431 and P = 0.406, respectively). The images were corrected for attenuation with a 68 Ge transmission scan and reconstructed using filtered back projection (Hanning filter, 5 mm full width at half maximum) and fifteen 6.5 mm-thick transaxial slices were obtained (total axial field of view 9.75 cm; covering area from the canto-meatal line upwards; part of cerebral cortex from vertex downward not covered). 3 ) on two adjacent transaxial PET slices. There were no significant differences in the pre-and post-AMPT sizes of the ROIs of the striata and cerebellum for the [ 11 C]SCH23390 scans (two-tailed paired Student's ttest: df = 5, P = 0.315 and P = 0.322, respectively) and for the [ 11 C]raclopride scans (two-tailed paired Student's t-test: df = 5, P = 0.424 and P = 0.345, respectively). For [
Image analysis
11 C]raclopride PET data, ROIs selected directly from the PET images have been shown to be almost identical to those obtained from coregistered MRI images. 37 The D 2 RBP, the product of the total D 2 R density (B max ) and the affinity (1/K d ) of [ 11 C]raclopride for D 2 R, was calculated using the simplified 3-parameter reference tissue model (SRTM). 38 For [ 11 C]raclopride PET data, the SRTM has been shown to provide similar results as the 4-parameter reference tissue model, 38 whereas the 4-parameter reference tissue model produced similar results as 1-and 2-tissue compartment models requiring metabolite-corrected plasma curves 39, 40 and as the sustained equilibrium method after bolus plus continuous infusion. 40 The SRTM has also been successfully used for [ 11 C]SCH23390 PET data. 38, 41 The SRTM was applied using the JAVA-based dedicated software PMOD. 42 3 Similarly, since in mice the D 1 RBP decrease was dose-dependent after administration of reserpine 16 or flunitrazepam, 17 we expected a correlation between the fractional D 1 RBP decrease and baseline DA concentration.
Outcome measures
Statistical analyses
Data were monitored for meeting the criteria for a normal distribution by testing for skewness, curtosis and outlyers, and for homogeneity of variance. 44 Correlations between PET data and clinical parameters were tested for using Pearson's product-moment correlation coefficient (r) if the criteria for a normal distribution were met and using Spearman's rank correlation coefficient (rho) if these criteria were not met. AMPT effects on clinical ratings and plasma levels were assessed by repeated measures ANOVA if the criteria for a normal distribution and homogeneity of variance were met and by Friedman's test if these criteria were not met. Similarly, AMPT effects on PET measurements were assessed by two-tailed paired Student's t-tests if the criteria were met and by Wilcoxon's signed ranks test if the criteria were not met. All tests were 2-tailed and probability values of 0.05 were used as the significance level. No corrections for multiple comparisons were applied. Statistical analyses were performed with SPSS for Windows, release 10.0.0 (SPSS Inc, Chicago, IL, USA, 1999).
